Episodes (Page 21)
✨
Pfizer's policy outlook for 2025 discussed.
✨
Exploring advancements in eClinical technology.
✨
Snapshot of the atopic dermatitis market.
✨
Highlights from the Generics Bulletin's 2024 review.
✨
Site networks improve clinical trial efficiency and scalability.
✨
Zepbound outperforms Wegovy; Novartis/PTC's Huntington's deal.
✨
Discussion of the Psychedelic Symposium at UW-Madison.
Emma Wille
Summer Colling
✨
Arialys Therapeutics CEO discusses autoimmune neuropsychiatry.
Peter Flynn
✨
COVID-19 vaccine EUAs potentially vulnerable under new administration.
✨
Emerging class of oncology drugs: bispecific antibodies.
David Dahan
Neha Anand
✨
Using tRNA as a therapeutic modality for rare diseases.
Michelle Werner
✨
Biopharma evolution through collaboration and precision medicine.
Izabela Chmielewska
Kevin Grogan
Natasha Choukkar
✨
Trump's potential threat to the FDA.
✨
Preview of the 2024 Scrip Awards.
Verona Pharma Interview
✨
Potential impact of new administration on FDA user fees.
✨
Novo's semaglutide shows promise in NASH.
✨
Entry into the obesity market and AbbVie's schizophrenia failure.
✨
Robert F. Kennedy Jr.'s potential impact on HHS and FDA.
Gerardo Ubaghs
Jason Silvers
✨
Analysis of declining biopharma M&A metrics in Q2/Q3.
Michael McCaughan
✨
Mapping the immune system using AI to predict drug responses.
Noam Solomon